Board Change • May 21
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Board Member Vasiliki Kefalas was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공시 • Mar 15
Lavipharm S.A., Annual General Meeting, Jul 03, 2025 Lavipharm S.A., Annual General Meeting, Jul 03, 2025. 공시 • Nov 01
Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024 Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024 Reported Earnings • Sep 21
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023). 공시 • Sep 02
Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024 Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024 Valuation Update With 7 Day Price Move • Jul 13
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to €1.02, the stock trades at a trailing P/E ratio of 71.9x. Average trailing P/E is 29x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 51% over the past year. Reported Earnings • May 29
First quarter 2024 earnings released First quarter 2024 results: EPS: €0.005. Revenue: €13.2m (down 4.6% from 1Q 2023). Net income: €780.0k (up 32% from 1Q 2023). Profit margin: 5.9% (up from 4.3% in 1Q 2023). 공시 • May 01
Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024 Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024 New Risk • Apr 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 05
Full year 2023 earnings released Full year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue. 공시 • Mar 01
Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024 Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024 New Risk • Jan 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin). New Risk • Nov 10
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 2.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Profit margins are more than 30% lower than last year (0.5% net profit margin). 공시 • Nov 01
Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023 Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023 Board Change • Oct 19
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 24
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022). Board Change • Sep 20
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Sep 01
Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023 Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023 Board Change • May 10
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Mar 21
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 17
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 17
First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021) First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses. Board Change • Aug 31
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.